
n3 PUFAs (Mean ± SD)

Placebo (Mean ± SD)

Mean Difference

95 % CI Pvalue


Sural nerve
    
aSAP1(μV)

9.95 (5.52–16.40)

5.50 (3.40–14.10)



.033***

aSAP 2^{a}

6.30 (4.60–10.30)

.00 (.00–7.32)
 
.052^{b}

%Change^{c}

− 36.68

− 100.00
  
SCV1(m/s)

43.99 ± 15.17

44.82 ± 6.27

−.83

−6.44 to 4.78, .766*

SCV 2

42.29 ± 15.51

29.67 ± 13.01

12.24

2.22 to 22.26, .018**

% Change

−3.84

− 33.80
  
Ulnar nerve
    
aSAP1(μV)

27.90 (16.82–42.77)

17.50 (12.40–35.50)



.144***

a SAP 2

22.80 (6.20–27.30)

10.14 (2.70–18.60)
 
.430^{b}

% Change

− 18.28

− 42.06
  
SCV1(m/s)

51.66 ± 8.34

50.15 ± 8.23

1.50

−2.51 to 5.52, .457*

SCV 2

44.08 ± 11.14

42.62 ± 7.26

.98

−4.61 to 6.57, .726**

% Change

− 14.66

− 15.01
  

aSAP sensory action potential amplitude, SCV sensory conduction velocity
 *P value is reported based on IndependentSamples TTest
 **P value is reported based on the analysis of covariance, adjusted for baseline values
 ***P value is reported based on the Mann–Whitney U Test

^{a}One month after the cessation of chemotherapy

^{b}
P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)

^{c}Percent change in proportion to the baseline values